Skip to content

Study on the integrated control of infectious diseases by traditional Chinese medicine--Research on the integrated control program of chronic hepatitis B by traditional Chinese and western medicine

Study on the integrated control of infectious diseases by traditional Chinese medicine--Research on the integrated control program of chronic hepatitis B by traditional Chinese and western medicine

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000119
Enrollment
Unknown
Registered
2024-07-04
Start date
2024-05-13
Completion date
Unknown
Last updated
2024-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatitis B

Interventions

treatment group:Yinqi sanhuang detoxification soup formula granules combined with entecavir
control subjects:Herbal placebo pellets combined with entecavir

Sponsors

Guang'anmen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Meet the diagnostic criteria for chronic hepatitis B; 2) Patients who meet the diagnostic criteria of liver fibrosis; 3) Meet the TCM diagnostic criteria of liver depression and spleen deficiency, and damp-heat internal stagnation; 4) Age between 18-70 years old, gender is not limited; 5) Willing to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Patients with hepatic fibrosis caused by other liver disease etiologies; 2) Patients with cirrhosis, primary liver cancer and other tumors; 3) Pregnant or lactating women, allergic patients; 4) Patients with combined serious heart, brain, lung, kidney, hematopoietic, immune and other systemic diseases; 5) Other conditions that the investigator thinks are not suitable for enrollment.

Design outcomes

Primary

MeasureTime frame
LMS;

Secondary

MeasureTime frame
Hepatitis B 5 test;blood routine examination;Abdominal ultrasound;electrocardiogram;Hepatitis B DNA test;APRI;Urine routine\Stool-RT;Hepatofibrillar quadruple test;B-scan ultrasonography.;liver function;

Countries

China

Contacts

Public ContactJiuchong Wang

Guang'anmen Hospital

15911136239@126.com15911136239

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026